Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUNA: Contraceptive Efficacy and Safety of N0999
NCT07714616Phase 3Not yet recruiting
- Sponsor
- Eurofarma
- Start
- May 2027
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial in contraception, sponsored by Eurofarma. Primary endpoint: Contraceptive Efficacy Assessed by Pearl Index in Participants Aged <=35 Years at 52 weeks. Planned start May 2027; status: not yet recruiting.
02
Conditions
contraception
Beyond the preview
Go deeper on NCT07714616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07714616.